What’s the latest on ADT research?

Key sentence from the paper: “All clinical trials of newer agents… in [metastatic castrate-resistant prostate cancer] include patients who maintain castrate levels of testosterone, and so clinical practice should adhere to this principle of continuing ADT when initiating abiraterone, enzalutamide or chemotherapy.

Read More

If one is on short-term ADT, does the duration of concurrent anti-androgen matter?

Key sentence from the paper: “… for men with no or minimal comorbidity, it appears that the delivery of full versus dose-reduced [anti-androgens] was not associated with prolonged survival…suggesting that supplementing the LHRH agonist therapy with and [anti-androgen] for ~4 rather than 6 months may be sufficient to minimize death from [prostate cancer] and prolong survival as compared with no ADT use.

Read More